Quantcast

Latest NuPathe Inc. Stories

Migraine Skin Patch Approved By The FDA
2013-01-20 07:24:05

redOrbit Staff & Wire Reports - Your Universe Online The Food and Drug Administration (FDA) has approved Zecuity, a skin patch used to treat migraine headaches, making it the first product of its kind to be cleared for sale in the US. Zecuity is manufactured by Pennsylvania-based NuPathe Inc, and according to Bloomberg reporter Ryan Flinn, it uses a “mild electrical current” to administer sumatriptan, “the most-prescribed migraine headache medication” in...

2008-07-24 09:00:25

NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced that the company has raised $30 million in a recently completed Series B equity financing. The financing was led by investments from two top venture capital funds: Quaker BioVentures and SR One Ltd., the venture capital arm of GSK. Previous investors, Safeguard Scientifics, Inc (NYSE:SFE), Bay City Capital/Birchmere Ventures,...

2008-06-30 12:02:03

NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development. NP101 combines NuPathe's SmartRelief(TM) proprietary iontophoretic transdermal technology with sumatriptan, the most widely prescribed treatment for acute migraine in the United States and the active ingredient in...

2008-06-16 09:00:10

NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced that Jane Hollingsworth, chief executive officer, will present at the Leerink Swann Emerging Technologies in Pain Conference at 2:00pm on June 23, 2008 at the Sofitel, New York Hotel located at 45 West 44th Street in NYC. Ms. Hollingsworth's presentation will focus on NP101, a novel transdermal patch in clinical...

2008-01-08 09:00:19

NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced that George Moonsammy, Ph.D. has been appointed Vice President of Development. Dr. Moonsammy has more than 30 years of domestic and international expertise in clinical studies. Dr. Moonsammy most recently served as Senior Vice President, Clinical, Regulatory, and Medical Affairs at Somerset Pharmaceuticals, Tampa,...

2007-01-16 09:01:38

CONSHOHOCKEN, Pa., Jan. 16 /PRNewswire/ -- NuPathe Inc., a privately held specialty pharmaceutical company, today announced the election of Michael Cola, president, Specialty Pharmaceutical Business, Shire Pharmaceuticals, to the NuPathe Board of Directors. Mr. Cola will also serve as a member of the Company's Audit Committee. Mr. Cola has more than 20 years of international pharmaceutical industry experience. He has served in leadership roles in product development and...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'